Lmr Partners LLP Zai Lab LTD Transaction History

Lmr Partners LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$22.72 - $31.49 $432,361 - $599,254	19,030 New	19,030 $462,000
Q2 2022 Aug 15, 2022	SELL	$23.14 - $49.68 $1.21 Million - $2.61 Million	-52,450 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$27.77 - $64.4 $1.46 Million - $3.38 Million	52,450 New	52,450 $2.41 Million
Q1 2020 May 15, 2020	SELL	$39.1 - $62.9 $317,687 - $511,062	-8,125 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$29.79 - $43.06 $233,166 - $337,030	-7,827 Reduced 49.07%	8,125 $337,000
Q3 2019 Nov 14, 2019	BUY	$30.47 - $37.65 $486,057 - $600,592	15,952 New	15,952 $516,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.43B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.